Tuesday, October 9th, 2:00pm-2:55pm

Novel delivery technologies, from synthetic nanoparticles to engineered virus shells, are now in the clinic, and data from recent clinical trial studies and FDA approvals are validating these methodologies. Should investors carve out larger portfolio allocations to delivery-focused companies or to the companies in-licensing these technologies? Will these technologies help move the needle on the industry’s success rate? Should companies outside the nucleic acids and generics race be stepping in and adding trials with these platforms sooner? This panel will survey recent trends from the clinical perspective, as well as the investment outlook and potential future breakthroughs for delivery technologies.